Clinical Trial: First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)

Brief Summary: The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).